BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) announced its earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.45, Yahoo Finance reports.
BriaCell Therapeutics Trading Down 7.5 %
BCTX traded down $0.06 during trading on Wednesday, hitting $0.77. 1,056,385 shares of the company’s stock were exchanged, compared to its average volume of 1,639,271. The stock has a 50 day moving average price of $0.80 and a 200 day moving average price of $1.15. BriaCell Therapeutics has a 1 year low of $0.46 and a 1 year high of $5.97. The firm has a market cap of $27.59 million, a P/E ratio of -0.66 and a beta of 1.34.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of BriaCell Therapeutics in a research report on Thursday, October 3rd.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Read More
- Five stocks we like better than BriaCell Therapeutics
- Transportation Stocks Investing
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What Investors Need to Know About Upcoming IPOs
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
